Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom

Hereditary Cancer in Clinical Practice

Volumn 12, Issue 1, 2014, Pages

  Harland, Mark ^a   Cust, Anne E ^b   Badenas, Celia ^c,d   Chang, Yu Mei ^a   Holland, Elizabeth A ^e   Aguilera, Paula ^c,d   Aitken, Joanne F ^f   Armstrong, Bruce K ^b   Barrett, Jennifer H ^a   Carrera, Cristina ^c,d   Chan, May ^a   Gascoyne, Joanne ^a   Giles, Graham G ^g,h   Agha Hamilton, Chantelle ^e   Hopper, John L ^g   Jenkins, Mark A ^g   Kanetsky, Peter A ⁱ   Kefford, Richard F ^e   Kolm, Isabel ^e   Lowery, Johanna ^j   Malvehy, Josep ^c,d   Ogbah, Zighereda ^c   Puig Butille, Joan Anton ^c,d   Orihuela Segalés, Jordi ^k   Randerson Moor, Juliette A ^a   Schmid, Helen ^e   Taylor, Claire F ^j   Whitaker, Linda ^a   Bishop, D Timothy ^a   Mann, Graham J ^e   Newton Bishop, Julia A ^a   Puig, Susana ^c,d   more..

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c HOSPITAL CLÍNIC   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e WESTMEAD HOSPITAL   (Australia)

^f VIERTEL CENTRE FOR RESEARCH IN CANCER CONTROL   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h CANCER EPIDEMIOLOGY CENTRE   (Australia)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF LEEDS   (United Kingdom)

^k Lafarge Cementos y Finanzauto   (Spain)

more..

Author keywords

CDKN2A; Family history; Melanoma; Multiple primaries; Population based

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; ARTICLE; AUSTRALIA; CDKN2A GENE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; EXON; FAMILY HISTORY; FEMALE; GENE; GENETIC SCREENING; GERMLINE MUTATION; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PENETRANCE; POPULATION BASED CASE CONTROL STUDY; PREDICTIVE VALUE; PREVALENCE; PROBABILITY; PROTEIN DOMAIN; SPAIN; UNITED KINGDOM; WILD TYPE;

EID: 84928727401     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-12-20     Document Type: Article

References (34)

1. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J: Cancer Incidence in Five Continents. Lyon: IARC Scientific Publications; 1997.
2. Thompson JF, Scolyer RA, Kefford RF: Cutaneous melanoma in the era of molecular profiling. Lancet 2009, 374:362-365. 10.1016/S0140-6736(09)61397-0
3. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994, 8:23-26.
4. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996, 12:97-99. 10.1038/ng0196-97
5. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B: Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998, 7:209-216. 10.1093/hmg/7.2.209
6. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, Leachman SA: Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol 2006, 126:660-666. 10.1038/sj.jid.5700094
7. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, MacKie RM, Magnusson V, Mann GJ, et al.: Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007, 44:99-106. Epub 2006 Aug 2011
8. Pedace L, De Simone P, Castori M, Sperduti I, Silipo V, Eibenschutz L, De Bernardo C, Buccini P, Moscarella E, Panetta C, Ferrari A, Grammatico P, Catricalà C: Clinical features predicting identification of CDKN2A mutations in Italian patients with familial cutaneous melanoma. Cancer Epidemiol 2011, 35:e116-e120. 10.1016/j.canep.2011.07.007
9. Maubec E, Chaudru V, Mohamdi H, Blondel C, Margaritte-Jeannin P, Forget S, Corda E, Boitier F, Dalle S, Vabres P, Perrot JL, Lyonnet DS, Zattara H, Mansard S, Grange F, Leccia MT, Vincent-Fetita L, Martin L, Crickx B, Joly P, Thomas L, Bressac-de Paillerets B, Avril MF, Demenais F, French Familial Melanoma Study Group: Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. J Am Acad Dermatol 2012, 67:1257-1264. 10.1016/j.jaad.2012.05.014
10. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ: CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998, 338:879-887. 10.1056/NEJM199803263381305
11. Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S, Langmark F, Loeb M, Akslen LA, Molven A, Andresen PA: Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 2008, 47:175-184. 10.1002/gcc.20518
12. Berwick M, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Busam K, From L, Mujumdar U, Wilcox H, Begg CB, GEM Study Group: The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev 2006, 15:1520-1525. 10.1158/1055-9965.EPI-06-0270
13. Puig S, Malvehy J, Badenas C, Ruiz A, Jimenez D, Cuellar F, Azon A, Gonzalez U, Castel T, Campoy A, Herrero J, Martí R, Brunet-Vidal J, Milà M: Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 2005, 23:3043-3051. 10.1200/JCO.2005.08.034
14. Larre Borges A, Cuellar F, Puig-Butille JA, Scarone M, Delgado L, Badenas C, Mila M, Malvehy J, Barquet V, Nunez J, Laporte M, Fernández G, Levrero P, Martínez-Asuaga M, Puig S: CDKN2A mutations in melanoma families from Uruguay. Br J Dermatol 2009, 161:536-541. 10.1111/j.1365-2133.2009.09242.x
15. Whiteman DC, Milligan A, Welch J, Green AC, Hayward NK: Germline CDKN2A mutations in childhood melanoma. J Natl Cancer Inst 1997, 89:1460.
16. Cust AE, Harland M, Makalic E, Schmidt D, Dowty JG, Aitken JF, Agha-Hamilton C, Armstrong BK, Barrett JH, Chan M, Chang YM, Gascoyne J, Giles GG, Holland EA, Kefford RF, Kukalizch K, Lowery J, Randerson-Moor JA, Schmid H, Taylor CF, Whitaker L, Hopper JL, Newton-Bishop JA, Mann GJ, Bishop DT, Jenkins MA: Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK. J Med Genet 2011, 48:266-272. 10.1136/jmg.2010.086538
17. Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, Affleck P, Leake S, Haynes S, Karpavicius B, Karpavicius B, Marsden J, Gerry E, Bale L, Bertram C, Field H, Barth JH, Silva Idos S, Swerdlow A, Kanetsky PA, Barrett JH, Bishop DT, Bishop JA: Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 2009, 45:3271-3281. 10.1016/j.ejca.2009.06.011
18. Cust AE, Schmid H, Maskiell JA, Jetann J, Ferguson M, Holland EA, Agha-Hamilton C, Jenkins MA, Kelly J, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Mann GJ: Population-based, case-control-family design to investigate genetic and environmental influences on melanoma risk: Australian Melanoma Family Study. Am J Epidemiol 2009, 170:1541-1554. 10.1093/aje/kwp307
19. Harland M, Goldstein AM, Kukalizch K, Taylor C, Hogg D, Puig S, Badenas C, Gruis N, Ter Huurne J, Bergman W, Hayward NK, Stark M, Tsao H, Tucker MA, Landi MT, Scarra GB, Ghiorzo P, Kanetsky PA, Elder D, Mann GJ, Holland EA, Bishop DT, Bishop JN, GenoMEL, the Melanoma Genetics Consortium: A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur J Cancer 2008, 44:1269-1274. 10.1016/j.ejca.2008.03.005
20. Pjanova D, Engele L, Randerson-Moor JA, Harland M, Bishop DT, Newton Bishop JA, Taylor C, Debniak T, Lubinski J, Kleina R, Heisele O: CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population. Melanoma Res 2007, 17:185-191. 10.1097/CMR.0b013e328014a2cd
21. Taylor CF: Mutation scanning using high-resolution melting. Biochem Soc Trans 2009, 37:433-437. 10.1042/BST0370433
22. Bertram CG, Gaut RM, Barrett JH, Pinney E, Whitaker L, Turner F, Bataille V, Dos Santos Silva I, JS A, Bishop DT, Newton Bishop JA: An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. J Invest Dermatol 2002, 119:961-965. 10.1046/j.1523-1747.2002.01825.x
23. Debniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Debniak B, Zaluga E, Maleszka R, Kladny J, Gorski B, Cybulski C, Gronwald J, Kurzawski G, Lubinski J: CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 2005, 65:835-839.
24. Kumar R, Smeds J, Berggren P, Straume O, Rozell BL, Akslen LA, Hemminki K: A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int J Cancer 2001, 95:388-393. 10.1002/1097-0215(20011120)95:6<388::AID-IJC1069>3.0.CO;2-6
25. Lamperska KM, Przybyla A, Kycler W, Mackiewicz A: The CDKN2a common variants: 148 Ala/Thr and 500 C/G in 3'UTR, and their association with clinical course of melanoma. Acta Biochim Pol 2007, 54:119-124.
26. Spica T, Portela M, Gerard B, Formicone F, Descamps V, Crickx B, Ollivaud L, Archimbaud A, Dupin N, Wolkenstein P, Vitoux D, Lebbe C, Saiag P, Basset-Seguin N, Fargnoli MC, Grandchamp B, Peris K, Soufir N, MELAN-COHORT: The A148T variant of the CDKN2A gene is not associated with melanoma risk in the French and Italian populations. J Invest Dermatol 2006, 126:1657-1660. 10.1038/sj.jid.5700293
27. Orlow I, Begg CB, Cotignola J, Roy P, Hummer AJ, Clas BA, Mujumdar U, Canchola R, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Wilcox H, Busam K, From L, Berwick M, GEM Study Group: CDKN2A germline mutations in individuals with cutaneous malignant melanoma. J Invest Dermatol 2007, 127:1234-1243. 10.1038/sj.jid.5700689
28. Miller PJ, Duraisamy S, Newell JA, Chan PA, Tie MM, Rogers AE, Ankuda CK, von Walstrom GM, Bond JP, Greenblatt MS: Classifying variants of CDKN2A using computational and laboratory studies. Hum Mutat 2012, 32:900-911.
29. Soufir N, Ribojad M, Magnaldo T, Thibaudeau O, Delestaing G, Daya-Grosjean L, Rivet J, Sarasin A, Basset-Seguin N: Germline and somatic mutations of the INK4a-ARF gene in a xeroderma pigmentosum group C patient. J Invest Dermatol 2002, 119:1355-1360. 10.1046/j.1523-1747.2002.19603.x
30. Harland M, Mistry S, Bishop DT, Newton Bishop JA: A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 2001, 10:2679-2686. 10.1093/hmg/10.23.2679
31. Nikolaou V, Kang X, Stratigos A, Gogas H, Latorre MC, Gabree M, Plaka M, Njauw CN, Kypreou K, Mirmigi I, Stefanaki I, Tsao H: Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma. Br J Dermatol 2011, 165:1219-1222. 10.1111/j.1365-2133.2011.10551.x
32. Goldstein AM, Stacey SN, Olafsson JH, Jonsson GF, Helgason A, Sulem P, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Kjartansson J, Kostic J, Masson G, Kristjansson K, Gulcher JR, Kong A, Thorsteinsdottir U, Rafnar T, Tucker MA, Stefansson K: CDKN2A mutations and melanoma risk in the Icelandic population. J Med Genet 2008, 45:284-289. 10.1136/jmg.2007.055376
33. Murali R, Haydu LE, Long GV, Quinn MJ, Saw RP, Shannon K, Spillane AJ, Stretch JR, Kefford RF, Thompson JF, Scolyer RA: Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma. Ann Surg Oncol 2012, 19:1782-1789. 10.1245/s10434-012-2265-y
34. Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarra G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, et al.: Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009, 61:677 e671-614.